Results 71 to 80 of about 1,942 (154)

Pharmacotherapy in paediatric epilepsy: from trial and error to rational drug and dose selection – a long way to go [PDF]

, 2016
Whereas ongoing efforts in epilepsy research focus on the underlying disease processes, the lack of a physiologically-based rationale for drug and dose selection contributes to inadequate treatment response in children.
Alvarez-Jimenez, R, Danhof, M, Della Pasqua, O, van Dijkman, SC   +3 more
core  

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
Obesity, MASH and Statins: Insights from a PBPK/PD Zonal Liver Model. ABSTRACT Statins are frequently prescribed for hyperlipidemia, a common comorbidity in patients with obesity and/or metabolic dysfunction‐associated steatohepatitis (MASH). However, limited knowledge exists on how MASH may alter statin disposition within hepatocytes where the statin ...
William A. Murphy, Noora Sjöstedt, Mailys De Sousa Mendes, Mattie Hartauer, Kim L. R. Brouwer, Sibylle Neuhoff   +5 more
wiley   +1 more source

Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan [PDF]

BACKGROUND: The antibody-drug conjugate sacituzumab govitecan is approved for metastatic triple-negative breast cancer and has shown promising results in various other types of cancer.
Bakker, J L, Croes, Sander, de Rouw, Nikki, Dezentjé, Vincent O, Guchelaar, Henk-Jan, Hendrikx, Jeroen J M A, Kroep, Judith R, Mathijssen, Ron H J, Moes, Dirk J A R, Munnink, Thijs H Oude, Smit, Egbert F, Ter Heine, Rob, van den Heuvel, Michel M, van Erp, Nielka P, van Kats, Maartje, Zwaveling, Juliette   +15 more
core   +7 more sources

Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT A physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors and recombinant supersomes demonstrated that niraparib is specifically metabolized by ...
Gareth J. Lewis, Roxanne C. Jewell, Anu Shilpa Krishnatry, Kunal S. Taskar   +3 more
wiley   +1 more source

DoR Communicator - April 2014 [PDF]

, 2014
The April 2014 issue of the Division of Research newsletter.https://digitalcommons.fiu.edu/research_newsletter/1000/thumbnail ...
Division of Research, Florida International University
core  

Establishing the Dissolution Bioequivalence Safe Space for Immediate Release Formulation of Baclofen using Physiologically based Biopharmaceutics Modeling [PDF]

Clinical bioequivalence assessment is one of the critical aspects in the product development, since these studies are helpful in establishing the equivalence between a generic product and its reference-listed drug as per regulatory requirements ...
Anuj K. Saini*, Mukesh Gupta1 and Ajay Lale
core   +2 more sources

Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model

The AAPS Journal
AbstractRitlecitinib, an orally available Janus kinase 3 and tyrosine kinase inhibitor being developed for the treatment of alopecia areata (AA), is highly soluble across the physiological pH range at the therapeutic dose. As such, it is expected to dissolve rapidly in any in vitro dissolution conditions.
Anas Saadeddin, Vivek Purohit, Yeamin Huh, Mei Wong, Aurelia Maulny, Martin E. Dowty, Kazuko Sagawa   +6 more
openaire   +2 more sources

Evolving Landscape of Precision Medicine in Bladder Cancer: From Challenges to Clinical Impact

iLABMED, Volume 3, Issue 4, Page 427-447, December 2025.
Evolving Landscape of Precision Medicine in Bladder Cancer. Image created with BioRender.com. ABSTRACT Bladder cancer (BCa) remains one of the most challenging urological malignancies to treat because of its marked molecular heterogeneity, high recurrence rates, and variable therapeutic responses.
Ting Ye, Javeria Qadir, Guangjie Peng, Liyuan Liu, Liang Cheng   +4 more
wiley   +1 more source

Mass spectrometry and n-in-one analytics in early drug discovery : combinatorial chemistry libraries, lipophilicity and absorption screening [PDF]

, 2010
This thesis describes current and past n-in-one methods and presents three early experimental studies using mass spectrometry and the triple quadrupole instrument on the application of n-in-one in drug discovery.
Kangas, Heli
core  

Artificial Intelligence Meets Bioequivalence: Using Generative Adversarial Networks for Smarter, Smaller Trials

Machine Learning and Knowledge Extraction
This study introduces artificial intelligence as a powerful tool to transform bioequivalence (BE) trials. We apply advanced generative models, specifically Wasserstein Generative Adversarial Networks (WGANs), to create virtual subjects and reduce the ...
Anastasios Nikolopoulos, Vangelis D. Karalis   +1 more
doaj   +1 more source